Literature DB >> 24391420

Nephrogenic diabetes insipidus : Old deletion, new effect. A case report of a family from Greece.

D Tramma1, S Kalamitsou1.   

Abstract

Congenital, X-linked, Nephrogenic Diabetes Insipidus (NDI) is a rare disorder in which the kidney is insensitive to the antidiuretic hormone, vasopressin. The gene responsible for this type of NDI, the V2 vasopressin receptor, has been cloned and mapped to Xq28. We report the case of a boy, 2.5 month old, who presented with nephrogenic diabetes insipidus (NDI). The mother and the 7 year old sister of the boy also had the NDI phenotype but did not seek medical attention until the presentation of the boy to our department. The mutational analysis of the patient showed the R337stop mutation, also founded to the mother's genotype analysis. The allele separation in mother revealed the second X chromosomal allele with a 12- bp in-frame deletion. The same in-frame deletion was also found in his sister's genotype. This deletion of four amino acids (Arg-247 to Gly-250) has been previously described but was suggested not to be linked with the NDI phenotype. However, in our case, the only possible cause of NDI phenotype in the boy's sister was the 12-bp in-frame deletion.

Entities:  

Keywords:  12bp-ICL3 deletion mutant; nephrogenic diabetes insipidus

Year:  2011        PMID: 24391420      PMCID: PMC3876854     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  10 in total

1.  Recessive type of nephrogenic diabetes insipidus.

Authors:  Annemie Vandermarliere; Bart Maes; Yves Vanrenterghem
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Severe bladder dysfunction in a family with ADH receptor gene mutation responsible for X-linked nephrogenic diabetes insipidus.

Authors:  Tim Ulinski; Christine Grapin; Veronique Forin; Rosa Vargas-Poussou; Georges Deschênes; Albert Bensman
Journal:  Nephrol Dial Transplant       Date:  2004-11       Impact factor: 5.992

3.  Urological complications of congenital nephrogenic diabetes insipidus--long-term follow-up of one patient.

Authors:  M Hora; T Reischig; O Hes; J Ferda; J Klecka
Journal:  Int Urol Nephrol       Date:  2006-11-16       Impact factor: 2.370

Review 4.  [Congenital nephrogenic diabetes insipidus].

Authors:  D Morin; A L Delenne; A Kervran
Journal:  Arch Pediatr       Date:  2005-01       Impact factor: 1.180

5.  Nephrogenic diabetes insipidus caused by mutation of Tyr205: a key residue of V2 vasopressin receptor function.

Authors:  Katrin Sangkuhl; Holger Römpler; Wibke Busch; Beate Karges; Torsten Schöneberg
Journal:  Hum Mutat       Date:  2005-05       Impact factor: 4.878

6.  V2 vasopressin receptor dysfunction in nephrogenic diabetes insipidus caused by different molecular mechanisms.

Authors:  T Schöneberg; A Schulz; H Biebermann; A Grüters; T Grimm; K Hübschmann; G Filler; T Gudermann; G Schultz
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

7.  Response to indomethacin and hydrochlorothiazide in nephrogenic diabetes insipidus.

Authors:  L Monnens; A Jonkman; C Thomas
Journal:  Clin Sci (Lond)       Date:  1984-06       Impact factor: 6.124

8.  V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis.

Authors:  Nicole Schliebe; Rainer Strotmann; Kathy Busse; Doreen Mitschke; Heike Biebermann; Lutz Schomburg; Josef Köhrle; Jörg Bär; Holger Römpler; Jürgen Wess; Torsten Schöneberg; Katrin Sangkuhl
Journal:  Am J Physiol Renal Physiol       Date:  2008-08-20

Review 9.  AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance.

Authors:  Elias Spanakis; Edrice Milord; Claudia Gragnoli
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

10.  Correlation between clinical phenotypes and X-inactivation patterns in six female carriers with heterozygote vasopressin type 2 receptor gene mutations.

Authors:  Mari Satoh; Sayaka Ogikubo; Atsuko Yoshizawa-Ogasawara
Journal:  Endocr J       Date:  2008-03-07       Impact factor: 2.349

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.